000143001 001__ 143001
000143001 005__ 20240229112539.0
000143001 0247_ $$2doi$$a10.1016/j.cgh.2019.01.014
000143001 0247_ $$2pmid$$apmid:30659991
000143001 0247_ $$2ISSN$$a1542-3565
000143001 0247_ $$2ISSN$$a1542-7714
000143001 0247_ $$2altmetric$$aaltmetric:65386563
000143001 037__ $$aDKFZ-2019-00626
000143001 041__ $$aeng
000143001 082__ $$a610
000143001 1001_ $$0P:(DE-HGF)0$$aRan, Tao$$b0$$eFirst author
000143001 245__ $$aCost-effectiveness of Colorectal Cancer Screening Strategies-a Systematic Review.
000143001 260__ $$aNew York, NY$$bElsevier Science$$c2019
000143001 3367_ $$2DRIVER$$aarticle
000143001 3367_ $$2DataCite$$aOutput Types/Journal article
000143001 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1567430293_12232$$xReview Article
000143001 3367_ $$2BibTeX$$aARTICLE
000143001 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143001 3367_ $$00$$2EndNote$$aJournal Article
000143001 520__ $$aWidespread screening for colorectal cancer (CRC) has reduced its incidence and mortality. Previous studies investigated the economic effects of CRC screening. We performed a systematic review to provide up to date evidence of the cost effectiveness of CRC screening strategies by answering 3 research questions.We searched PubMed, NHS EED, SSCI, EconLit, and 3 supplemental databases for original articles published in English from January 2010 through December 2017. All monetary values were converted to United States (US) dollars (year 2016). For all research questions, we extracted, or calculated (if necessary), per-person costs and life years (LY) and/or quality-adjusted LYs (QALY), as well as the incremental costs per LY gained or QALY gained compared to the baseline strategy. A cost-saving strategy is defined as one that was less costly and equally or more effective than the baseline strategy. Net monetary benefit approach was used to answer research question 2.Our review comprised 33 studies (17 from Europe, 11 from North America, 4 from Asia, and 1 from Australia). Annual and biennial guaiac-based fecal occult blood tests, annual and biennial fecal immunochemical tests, colonoscopy every 10 years, and flexible sigmoidoscopy every 5 years were cost-effective (even cost saving in most US models) compared with no screening. Additionally, colonoscopy every 10 years was less costly and/or more effective than other common strategies in the US. Newer strategies such as computed tomographic colonography, every 5 or 10 years, were cost-effective compared to no screening.In an updated review, we found that common CRC screening strategies and computed tomographic colonography continued to be cost-effective compared to no screening. There were discrepancies among studies from different regions, which could be associated with the model types or model assumptions.
000143001 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143001 588__ $$aDataset connected to CrossRef, PubMed,
000143001 7001_ $$0P:(DE-HGF)0$$aCheng, Chih-Yuan$$b1
000143001 7001_ $$aMisselwitz, Benjamin$$b2
000143001 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$udkfz
000143001 7001_ $$0P:(DE-HGF)0$$aUbels, Jasper$$b4
000143001 7001_ $$0P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aSchlander, Michael$$b5$$eLast author$$udkfz
000143001 773__ $$0PERI:(DE-600)2102638-5$$a10.1016/j.cgh.2019.01.014$$gp. S1542356519300345$$n10$$p1969-1981.e15$$tClinical gastroenterology and hepatology$$v17$$x1542-3565$$y2019
000143001 909CO $$ooai:inrepo02.dkfz.de:143001$$pVDB
000143001 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143001 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143001 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143001 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143001 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143001 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143001 9141_ $$y2019
000143001 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN GASTROENTEROL H : 2017
000143001 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143001 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143001 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143001 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143001 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143001 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143001 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143001 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN GASTROENTEROL H : 2017
000143001 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143001 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000143001 9201_ $$0I:(DE-He78)C100-20160331$$kC100$$lGesundheitsökonomie$$x2
000143001 980__ $$ajournal
000143001 980__ $$aVDB
000143001 980__ $$aI:(DE-He78)C070-20160331
000143001 980__ $$aI:(DE-He78)C120-20160331
000143001 980__ $$aI:(DE-He78)C100-20160331
000143001 980__ $$aUNRESTRICTED